It plans to charge $390 a vial, or $2,340 for a five-day regimen, for direct government purchases by the U.S. or other developed countries

Five companies will be allowed to supply remdesivir to 127 mostly low- and middle-income countries

WHO warns of pandemic disaster in Africa and sees coronavirus as permanent; Jia Yueting’s Leshi finally being delisted; China gives consumers $2.7 billion

The rapid move by Japan’s usually conservative authorities comes days after the U.S. authorized the drug for emergency use on virus patients

Tourists hit the road in China for the Labor Day holiday after months of being cooped up; Shenyang expands virus testing; PBOC chief sees GDP rebounding

Research published this week shows remdesivir might be effective, or might not, though each of the three studies has its faults

Russia’s prime minister steps down with coronavirus; China clears pilot test of REITs to spur economy; BOC told to probe failed crude oil investment product

Positive results on Gilead’s Covid-19 drug cheer Wall Street; Chinese trying to get back from Russia face a high hurdle; Luckin delays annual financial report

Data posted accidentally to WHO website shows remdesivir didn’t improve patients’ condition in rigorous Chinese trials, which have since been discontinued

Report suggesting drug may work on Covid-19 lifts overall U.S. market though Gilead says findings aren’t complete; China confirms tests of central bank’s digital yuan

Lack of enough patients forces end of test of remdesivir for mild cases after trial in severe patients was halted Friday

Two-thirds of 53 patients treated with remdesivir improved, new study shows, but lead author cautions against definitive conclusions

Patients treated using AbbVie’s Kaletra died at a similar rate to those who only had standard care, peer-reviewed research shows

Wuhan Research Institute says it will withdraw its competing patent claim if Gilead pledges to work with China to fight coronavirus

Although remdesivir so far appears to be more effective at fighting the deadly virus than other antivirals, the evidence remains light

Move by Wuhan Institute of Virology would clear the way for clinical trials while balancing need to fight virus with China’s commitments to protect intellectual property

The aging population and a raft of lifestyle factors mean that more new cancer patients are emerging in China than anywhere else

Six other biotech companies file for listings on city’s exchange

American drugmaker to sell Solvaldi for one-fifth of its price in the U.S.